The incidence of cutaneous metastasis of solid tumors is rare. Breast cancer is commonly associated with skin metastases. The frequency of cutaneous metastasis of lung and larynx cancers is high in men. The most common site of cutaneous metastases is the anterior thorax, followed by the abdomen, head and neck, scalp, and extremities. The prognosis of patients with cutaneous metastases is poor. The median life expectancy after skin metastasis development in most patients is 6 months. This study reported a 55-year-old patient diagnosed with metastasized laryngeal squamous cell carcinoma in which 90% of cells exhibited PD-L1 expression. After treatment with the combination of pembrolizumab and cisplatin-fluorouracil chemotherapy, the patient developed multiple subcutaneous skin metastases on the lower extremities and back after the fourth cycle. The review of previous scientific literature in the English language revealed only 16 subcutaneous skin metastasis cases. However, the development of skin metastases after immunotherapy has not been previously reported. Thus, visceral metastases may progress rapidly in patients with skin metastases, contributing to poor prognosis.